Phase II study of lenvatinib plus pembrolizumab for disease progression after PD-1/PD-L1 immune checkpoint inhibitor in metastatic clear cell renal cell carcinoma (mccRCC): Results of an interim analysis Meeting Abstract

  

Authors:	Lee, C. H.; Shah, A. Y.; Makker, V.; Taylor, M. H.; Shaffer, D.; Hsieh, J. J.; Cohn, A. L.; DiSimone, C.; Pinto Marin, A.; Rasco, D. W.; Ribe, S. G.; Richards, D. A.; Stepan, D. E.; Dutcus, C. E.; Wu, J.; Schmidt, E. V.; Perini, R. F.; Motzer, R. J.
Abstract Title:	Phase II study of lenvatinib plus pembrolizumab for disease progression after PD-1/PD-L1 immune checkpoint inhibitor in metastatic clear cell renal cell carcinoma (mccRCC): Results of an interim analysis
Meeting Title:	44th ESMO Congress (ESMO 2019)
Journal Title:	Annals of Oncology
Volume:	30
Issue:	Suppl. 5
Meeting Dates:	2019 Sep 27-Oct 1
Meeting Location:	Barcelona, Spain
ISSN:	0923-7534
Publisher:	Oxford University Press
Date Published:	2019-10-01
Start Page:	mdz253.013
Language:	English
ACCESSION:	WOS:000491295503235
PROVIDER:	wos
DOI:	10.1093/annonc/mdz253.013
Notes:	Meeting Abstract: 1187PD -- Appears on pages v483-v484 of the abstract book -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/157330